Valsartan And Hydrochlorothiazide
Product Images NDC 53002-2788

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 53002-2788). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530022788)

The image shows the packaging label for Valsartan and Hydrochlorothiazide 320-25 mg tablets by RPK Pharmaceuticals, Inc. It includes 90 tablets, with directions to take 1 tablet daily. The label displays product NDC 53002-2788, usage instructions, storage information, lot number, expiration date, and spaces for clinic and patient details.*

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

A line graph showing the percentage of systolic blood pressure (SBP) less than 140 mmHg plotted against baseline SBP in mmHg. Four lines represent treatment groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The graph compares the efficacy of these treatments over a range of baseline SBP values.*

FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

A line graph comparing the percentage of diastolic blood pressure (DBP) below 90 mmHg against baseline DBP (90-110 mmHg) for four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The Valsartan HCT 320/25 mg group shows the highest percentage below 90 mmHg across the baseline range.*

FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

A line chart showing the percentage of patients with systolic blood pressure (SBP) below 130 mmHg based on baseline SBP (mmHg). The graph compares the effects of Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with respective distinct markers for each treatment group.*

FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

A line graph depicting the percentage of diastolic blood pressure (DBP) below 80 mmHg versus baseline DBP (mmHg) for four treatments: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The graph shows trends for each treatment group across baseline DBP values from 90 to 110 mmHg.*

FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Chemical structure of the active ingredient in Valsartan and Hydrochlorothiazide by RPK Pharmaceuticals, Inc., showing a sulfonamide-substituted aromatic ring with chlorine and amine groups attached.*

FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Chemical structure of valsartan, an angiotensin II receptor blocker, showing its molecular arrangement with various functional groups including a biphenyl group and tetrazole ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.